Treatment - Page 49 of 471 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with genetic abnormalities

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with genetic abnormalities

Posted by on Jun 30, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes for patients with chronic lymphocytic leukemia (CLL), with genetic abnormalities (mutated IGHV) and without del(17p)/TP53 mutation, who were treated with the iFCG (ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab) regimen.  This study concluded that this treatment regimen is...

Read More

Comparing the outcomes of robot-assisted versus video-assisted thoracic surgery for patients with non-small cell lung cancer.

Comparing the outcomes of robot-assisted versus video-assisted thoracic surgery for patients with non-small cell lung cancer.

Posted by on Jun 30, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the short-term and long-term effectiveness between video-assisted thoracic surgery (VATS) and robot-assisted thoracic surgery (RATS) for the treatment of patients with non-small cell lung cancer (NSCLC). The data showed that RATS is a good and safe technique compared with VATS in terms of short-term and long-term...

Read More

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Posted by on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of salvage radiotherapy (RT) in patients with recurrence of prostate cancer (PCa) after prostate surgery. The study found that salvage RT was effective in the management of PCa recurrence with manageable side effects. Some background Localized prostate cancer (PCa) is a form of cancer that...

Read More

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Posted by on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell The study aimed to understand the long-term outcomes of focal laser therapy (FLT) in patients with prostate cancer. The study showed that this treatment has long-term survival without recurrence in certain patients.   Some background Surgical removal of the prostate gland is often recommended as a treatment for...

Read More

Comparing safety and effectiveness of bipolar transurethral enucleation and resection in patients with benign prostatic hyperplasia.

Comparing safety and effectiveness of bipolar transurethral enucleation and resection in patients with benign prostatic hyperplasia.

Posted by on Jun 27, 2021 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study compared the safety and effectiveness of bipolar transurethral enucleation of the prostate (BipoLEP) to bipolar transurethral resection of the prostate (B-TURP) in the treatment of benign prostatic hyperplasia (BPH). The data showed that BipoLEP resulted in fewer adverse effects, complications, and faster...

Read More

Levodopa/carbidopa intestinal gel improves off symptoms in the long-term in patients with advanced Parkinson´s disease

Levodopa/carbidopa intestinal gel improves off symptoms in the long-term in patients with advanced Parkinson´s disease

Posted by on Jun 27, 2021 in Parkinson's Disease | 0 comments

In a nutshell This study reviewed the long-term effects of levodopa/carbidopa intestinal gel (LCIG; Duodopa®) in patients with Parkinson´s disease (PD) and wearing-off symptoms. This study concluded that LCIG reduced off-time and improved off-symptoms in the long-term in these patients. Some background PD is a chronic disorder that...

Read More

Evaluating long-term outcomes of rosuvastatin treatment to prevent heart complications

Evaluating long-term outcomes of rosuvastatin treatment to prevent heart complications

Posted by on Jun 27, 2021 in Coronary artery disease | 0 comments

In a nutshell This study evaluated the long-term effects of rosuvastatin (Crestor) compared to placebo in reducing heart complications. This study concluded that rosuvastatin helped lower the risk of major cardiovascular events (MACE) in the long-term. Some background Most MACEs such as heart attack and stroke happen in people who do...

Read More

Comparing pembrolizumab and brentuximab vedotin for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma.

Comparing pembrolizumab and brentuximab vedotin for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Jun 27, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors compared the safety and effectiveness of pembrolizumab (Keytruda) and brentuximab vedotin (BV; Adcetris) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The study found that pembrolizumab had better survival without cancer worsening compared to BV in these...

Read More

Which patients with advanced melanoma would benefit the most from a cancer vaccine?

Which patients with advanced melanoma would benefit the most from a cancer vaccine?

Posted by on Jun 27, 2021 in Melanoma | 0 comments

In a nutshell This study investigated which patients with advanced melanoma would benefit the most from a cancer vaccine. The study found that the vaccine was most effective in patients with stage IV melanoma who has surgery to remove the tumor completed all treatment doses. Some background Melanoma is an aggressive type of skin cancer. Treatment...

Read More

Inotuzumab ozogamicin with bosutinib for relapsed/refractory Philadelphia chromosome-positive ALL or lymphoid blast phase of CML

Inotuzumab ozogamicin with bosutinib for relapsed/refractory Philadelphia chromosome-positive ALL or lymphoid blast phase of CML

Posted by on Jun 27, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if a combination of inotuzumab ozogamicin (InO; Besponsa) and bosutinib (Bo; Bosulif) was safe and effective in patients with relapsed/refractory (r/r) Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) or lymphoid blast phase (BP) chronic myeloid leukemia...

Read More

Evaluating the long-term outcomes of apalutamide plus androgen deprivation therapy in metastatic castration-sensitive prostate cancer

Evaluating the long-term outcomes of apalutamide plus androgen deprivation therapy in metastatic castration-sensitive prostate cancer

Posted by on Jun 27, 2021 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The data showed that this combination improved survival, delayed castration resistance, and maintained the...

Read More

Effects of adherence to homone therapy after surgery and radiation on the outcomes of older patients with early-stage breast cancer

Effects of adherence to homone therapy after surgery and radiation on the outcomes of older patients with early-stage breast cancer

Posted by on Jun 13, 2021 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the effects of adherence to hormonal therapy (HT) and radiation on the outcomes of older patients with early-stage breast cancer (BC).   This study concluded that the lack of adherence to HT and omitting radiation can lead to poorer outcomes for these...

Read More